INTRODUCTION
Reports from different parts of the world suggest a range of incidence of posttransfusion hepatitis from approximately 7% in the USA,' 3.4% in one Dutch study2 to 2% in Sydney, Australia.3 The only available information for the UK shows an incidence of 2.4 % in patients undergoing cardiac surgery in Newcastleupon-Tyne. 4 Hepatitis in these studies included clinical and sub-clinical episodes (indicated by abnormal liver function tests after blood transfusion). The aetiology of jaundice in a patient who has previously received blood and/or blood products includes hepatitis B, Epstein-Barr virus and cytomegalovirus. Non-A, non-B hepatitis continues to be associated with blood transfusion, but there is little published evidence of the true incidence of this condition, its clinical importance or long-term consequences.5, 6 We report on a retrospective analysis of post-transfusion hepatitis notified to us from 1980 through 1984. Prior to this period, notification was anecdotal and follow-up tests on blood donors were minimal. The next step is notification of the patient to the NI Blood Transfusion Service with date(s) of transfusion and donation numbers of all blood and blood products. The investigations and follow-up include: a) identification of all volunteer blood donors implicated by the unique donation numbers; b) the relevant stored (-200C) donor serum is tested for hepatitis B surface antigen (HBsAg), antibody to hepatitis B surface and core antigens (anti HBs, anti HBc), and for liver function tests; c) recall of donor(s) for a fresh sample of blood to repeat the tests and ensure that implicated donors are excluded from blood donations until all investigations are completed.
METHODS

RESULTS
Sixteen patients with post-transfusion hepatitis were reported from 1980 to 1984 (see Table) . There was a sudden increase in the number of patients reported in 1984 which we attribute to a letter written by one of us (CB) in December 1983, to all haematologists in the province, stressing the importance of notification. further transmission to other patients through future blood donations. In the absence of a screening test,7 our present policy is empirical exclusion of any donor implicated in two instances of post-transfusion hepatitis. It is to be noted that, in one patient, the hepatitis was subsequently shown to be drug-induced. Non-transfusion-related causes must be considered early in the differential diagnosis.
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One donor who was HBsAg negative but anti-HBc positive transmitted hepatitis B to one patient. This is a rare occurrence but is a known possibility.8,9,10 The value and cost-effectiveness of screening every donation for anti-HBc has been debated."' 12,13 In Northern Ireland, the incidence of chronic asymptomatic carriers of hepatitis B is very low: one in 1500 healthy new donors is HBsAg positive. The risk of hepatitis B transmission from donors who are only anti-HBc positive in our region is estimated to be negligible and does not justify the high cost that such screening would entail.
No hepatitis B markers were detected in one patient although a donor involved was repeatedly positive for anti-HBc. The post-transfusion hepatitis in this patient was attributable to non-A, non-B infection. We have been unable to establish a satisfactory duration of follow-up with regard to hepatitis B markers in this case, although there are other reports of non-A, non-B transmission from donors who are positive only for anti-HBc.14 Blood products including platelet concentrates, fresh frozen plasma, cryoprecipitate and coagulation factor concentrates are known to transmit hepatitis but none of our present series of patients were exposed to these. The reported incidence of post-transfusion hepatitis shows great variation, the lowest being 2 % .3 There is little doubt that the apparently negligible incidence in Northern Ireland during the years 1980-1983 must be due to lack of notification. It is still uncertain how many cases are missed, and even among a small population like that of Northern Ireland it is difficult to hazard a guess at the true incidence of the disease. Of the non-B infections, non-A, non-B hepatitis is a significant problem particularly in terms of chronic liver damage, despite the mildness of the initial illness. We wish to thank Mrs C Shaw for typing the manuscript.
